Skip to main content

Table 5 Multivariable model of variables associated with receipt of two or more breast imaging exams in the 6–26 months after diagnosis among tested women (N = 731)

From: Endocrine therapy initiation, discontinuation and adherence and breast imaging among 21-gene recurrence score assay-eligible women under age 65

  OR (95% CI) P
Recurrence score    0.06
 Low or intermediate (ref)    
 High 0.49 (0.23–1.03)  
Age at diagnosis, years    0.08
 24–39 0.36 (0.14–0.90)  
 40–49 1.18 (0.72–1.92)  
 50–59 (ref)    
 60–63 1.23 (0.69–2.19)  
Stage    0.48
 I 1.22 (0.70–2.12)  
 II (ref)    
Chemotherapy    0.33
 Yes    
 No (ref) 1.29 (0.77–2.15)  
Histological grade    0.84
 1–2 (well/moderately differentiated) (ref)    
 3 (poorly or not differentiated) 1.06 (0.58–1.95)  
Nodal involvement    0.58
 N0 (ref)    
 N1mic/N1 1.27 (0.54–2.99)  
Surgery type    <0.001
 Breast-conserving surgery 3.75   
 Unilateral mastectomy (ref)    
  1. Nodal involvement: N0 no cancer in the lymph nodes; N1mic lymph node cancer that can only be seen under a microscope (<2 mm in size); N1 cancer at least 2 mm in size in at least one of three axillary lymph nodes